Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CSCIF · OTC · United States · Perfumes, Cosmetics & Other Toilet Preparations
In shortCOSCIENS Biopharma Inc. is loss-making.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -142.5% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -138.1% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -121.8% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 3.18× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -63.58× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -3.83 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -122.4% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 5 | 20/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 87.8% | 0/100 |
| Operating margin volatility | 89.5% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -19.9% | 0/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 5.3 | 15 | 7.1 | 9.6 | 7.5 |
| Cost of revenue | 0.1 | 6 | 4.2 | 4.9 | 4.9 |
| Gross profit | 5.2 | 8.6 | 2.9 | 4.7 | 2.6 |
| Research & development | 6.6 | 1.4 | 2 | 8.3 | 3 |
| Selling, general & admin | – | 2.9 | 5.5 | 10 | 10 |
| Operating income | (8.7) | 4.3 | (4.6) | (18) | (11) |
| Interest expense | – | 0.1 | 0.1 | 0.1 | 0.2 |
| Pre-tax income | (8.5) | 4.5 | (4.4) | (15) | (10) |
| Income tax | (0.1) | 1.1 | (0.9) | 0.1 | 0 |
| Net income | (8.4) | 3.4 | (3.5) | (15) | (10) |
| Diluted EPS | −$1.82 | $1.86 | −$1.89 | −$5.93 | −$3.27 |
| Diluted shares (millions) | 4.6 | 1.9 | 1.8 | 2.6 | 3.2 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−3.83 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Mar 25, 2026